Thelansis

Dry Age-Related Macular Degeneration Market Outlook Thelansis’s “Dry Age-Related Macular Degeneration Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dry Age-Related Macular Degeneration treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the grea...

 Age-related macular degeneration (AMD) is a progressive, degenerative disease that frequently results in a large scotoma in the central visual field, causing fixation and reading difficulties. Dry Age-Related Macular Degeneration is caused by the appearance of small yellow deposits called drusen, which form under the retina. These are the retina's accumulated waste products, which can grow in size. This can cause the retinal cells in the macula that process light to die, resulting in blurred vision. ·        In the United States, approximately 11 million individuals are affected by AMD alone, with a global prevalence of 170 million.   Thelansis’s “Dry Age-Related Macular Degeneration Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, ...